5-Year Survival Data of Durvalumab after Chemoradiotherapy for unresectable Stage III NSCLC - an Update from the PACIFIC Study-MedSci.cn

5-Year Survival Data of Durvalumab after Chemoradiotherapy for unresectable Stage III NSCLC - an Update from the PACIFIC Study

de Wit, M; Spigel, D; Faivre-Finn, C; Gray, J; Vicente, D; Planchard, D; Paz-Ares, L; Vansteenkiste, J; Garassino, M; Hui, R; Quantin, X; Rimner, A; Wu, YL; Ozguroglu, M; Lee, KH; Kato, T; Macpherson, E; Newton, M; Thiyagarajah, P; Antonia, S; Reck, M

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

5-Year Survival Data of Durvalumab after Chemoradiotherapy for unresectable Stage III NSCLC - an Update from the PACIFIC Study

科室

工具

服务